The first stock we take a look at is Model N (MODN.N) which is up over 34% on the day of their debut. This has brought the company nearly half-a-billion dollars.
Francis Gaskins, a partner at IPODesktop.com, an IPO research company commented; “They’re very unique. They’ve carved out pretty much an impenetrable market position in the life sciences area and they’re taking that success pattern into other vertical markets such as technology.” The company is also moving more into cloud, which is always of great interest to investors, because that’s based more on subscription revenue with additional recurring earnings.”
Model N is a company that provides revenue management software to life science and technology companies to help manage pricing, deals, contracts and rebates.
Valeant CEO J. Michael Pearson said; The acquisition of Obagi will be a valuable supplement to Valeant’s current dermatology portfolio and will further build upon our growing aesthetics franchise.” Obagi is best known for Nu-Derm, a topical prescription treatment for wrinkles and skin blotches. The company also sells products that complement injections of dermal fillers and botulinum toxins.
Last but not least we find Gevo Inc. (GEVO) trading up in value over 10% this morning on a federal court ruling. The U.S. biofuel producer, partly prevailed in its bid for a federal court ruling saying that it doesn’t infringe on a Butamax Advanced Biofuels LLC patent for a method to commercially produce isobutanol.
Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. They are my opinions only. Trading stocks is risky — always be sure to know and understand your risk tolerance. You can incur substantial financial losses in any trade or investment. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser.